40% of pharma executives are baking expected savings from Generative AI into 2024 budgets
NEW YORK, Feb. 12, 2024 /PRNewswire/ -- The generative artificial intelligence (AI) transformation is well underway in pharma, and pharma companies have high confidence in its value. Already, 40% of executives say they are baking expected savings into their 2024 budget, and 60% have set targets for cost savings or productivity boosts, according to a recent Bain & Company survey.
- NEW YORK, Feb. 12, 2024 /PRNewswire/ -- The generative artificial intelligence (AI) transformation is well underway in pharma, and pharma companies have high confidence in its value.
- Already, 40% of executives say they are baking expected savings into their 2024 budget, and 60% have set targets for cost savings or productivity boosts, according to a recent Bain & Company survey .
- Generative AI is top of mind for most pharma companies, with 75% citing it as a C-suite and board priority.
- The best companies will establish an organizational center of gravity with several executives who act as generative AI champions.